FDA Approves Opdivo in Metastatic Melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Opdivo (nivolumab) injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

“About a year ago, in January, were these two massive fires in Los Angeles: the Palisades fire, and the Eaton Fire,” Sara Willa Ernst, reporter with The Cancer Letter, said on The Cancer Letter Podcast. On this week's episode, Sara and Jacquelyn Cobb, associate editor with The Cancer Letter, talk about their experience working as writer-and-editor duo on The Cancer Letter’s most recent cover story, which featured emerging data about the toxic exposure and cancer risk caused by the Eaton and Palisades fires—specifically focused on the firefighters who were sent to fight them. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login